10x Genomics, Inc.
TXG · Price history
Price at last available close
$83.62
−$6.42 (-7.13%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About 10x Genomics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
How they make money
10x Genomics generates revenue primarily through the sale of integrated solutions, including instruments, consumables, and software, to life sciences researchers. The business model relies on a razor-and-blade approach where customers purchase proprietary instruments and subsequently purchase recurring, high-margin consumables required to perform experiments.
Products & services
The company provides single cell and spatial biology platforms, including Chromium, Visium, and Xenium, along with associated reagents, microfluidic chips, and data analysis software.
Brands & revenue mix
Primary platform for single cell analysis.
Separate brand revenue is not available in this research.Source
Platform for spatial transcriptomics.
Separate brand revenue is not available in this research.Source
Platform for high-resolution spatial imaging.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
For the years ended December 31, 2025 and 2024, no single customer, including distributors, represented greater than 10% of the company's business.
Suppliers, materials & equipment
- Contract manufacturing and component suppliers — The company relies on various third-party manufacturers and suppliers for the production of instruments and consumables; specific supplier names are not disclosed.Source
Competitors
Strengths
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly EPS turned negative at -0.14 versus 0.28 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
34
Poor
Financial Strength
20
Business Quality / Moat
56
Management
40
Growth Quality
29
Risk / Durability
21
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
21
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
23/100
Building Historical Record
Model Score 23/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for TXG
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving TXG's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is TXG's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is TXG likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for TXG to reach sustainable profitability?
- •What future growth or profitability would be needed to justify TXG's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
21
Market Cap
$10.89B
P/E Ratio
-147.8
EPS
$-0.59
52-Week High
$95.16
52-Week Low
$11.16
Beta
2.08
Analyst Target
$66.50
Shares Outstanding
124.7M
Total Revenue
$616.9M
Total Debt
$78.8M
Dividend
No current dividend
Liquidation Value / Share
$6.62
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on TXG.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary technology platforms in single cell and spatial biology.
- +Strong intellectual property portfolio.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Intense competition and rapid technological change.
- −Dependence on third-party manufacturers and supply chain stability.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
26
Jul 24, 2026
Change
-0.2
points
Current Score
26
Oct 1, 2026
Category Changes
TXG decreased 0.2 points because Asset declined by 2.1 points.
Negative Contributors
- − Asset declined by 2.1 points
Projected Score
Projected Score
20
Projected Change
-5.0 points
Preliminary comparable-period financial changes suggest decline of approximately 5.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$83.62
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $616.9M | $642.8M | $610.8M | $618.7M | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $184.9M | $198.9M | $196.3M | $209.4M | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $432.0M | $443.9M | $414.5M | $409.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $226.8M | $238.6M | $264.7M | $270.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $297.0M | $316.1M | $344.3M | $343.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $520.4M | $554.8M | $609.0M | $674.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $28.0M | $3.9M | -$134.0M | -$205.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$88.4M | -$110.9M | -$194.6M | -$265.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $3K | $0.00 | $4K | $33K | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$74.9M | -$39.9M | -$177.7M | -$248.8M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $235K | $3.6M | $4.9M | $6.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$75.1M | -$43.5M | -$182.6M | -$255.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.59 | $-0.35 | $-1.52 | $-2.18 | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 130M | 125M | 120M | 117M | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 130M | 125M | 120M | 117M | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$151.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.14
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-9.2%
Cash Change
+26.4%
Margin Change
-31.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included revenue growth, EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 12.6%. EPS declined 150.0%. Cash increased 26.4%. Total debt declined 9.2%. Net income margin declined by 31.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
41
Smart Money
41
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
Torex Gold Targets Growth, C$350M Returns and Morelos Expansion
Rumor Mill · TXG
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial